Lipoprotein (a) Risk: Genetic Threat & Biotech Investment
- Okay, here's a cleaned-up and more readable version of the text, removing the extraneous HTML tags and formatting inconsistencies.
- Lipoprotein (a) [lp(a)] elevation is a hereditary disease that significantly increases the risk of cardiovascular disease.
- A new survey in the Asia-Pacific and Middle East shows that 66% of people do not undergo regular heart health checks, and nearly half of them do not...
Okay, here’s a cleaned-up and more readable version of the text, removing the extraneous HTML tags and formatting inconsistencies. I’ve also tried to maintain the original meaning and flow.
Cardiovascular disease (CVD) causes nearly 18 million deaths each year, more than all cancers combined.
Lipoprotein (a) [lp(a)] elevation is a hereditary disease that significantly increases the risk of cardiovascular disease. Even though it affects one-fifth of the world’s population, only a few people are tested.
A new survey in the Asia-Pacific and Middle East shows that 66% of people do not undergo regular heart health checks, and nearly half of them do not know that genes are related to heart disease.
Experts call for priority to improve public awareness of lipoprotein (a) in cardiovascular health management, and promote testing and care.
Cardiovascular disease (CVD) causes nearly 18 million deaths each year, more than all cancers combined, but a key genetic risk factor is rarely valued. Excessive lipoprotein (a), affecting one-fifth of the world’s population, is closely related to cardiovascular diseases such as heart attacks or strokes, but the current detection rate is still low and is often overlooked in heart health management.
Before World Heart Day (September 29), the Global Heart Hub and Novartis convened international medical experts to jointly organize the media education online seminar “Lp(a): Small (a) Make a big impact”, jointly discussing the risks of elevated lipoprotein (a) and its importance, calling for the integration of this under-recognized hidden risk into cardiovascular health policies to better prevent and respond to such diseases.
According to a questionnaire commissioned by Novartis in the Asia-Pacific and Middle East, two-thirds (66%) did not undergo regular heart health checks, while nearly half (45%) did not realize that genes are a risk factor for heart disease. In addition, only 22% of respondents have heard of the bioassay indicator of lipoprotein (a) or Lp(a), and only 7% have received relevant tests.
“Cardiovascular disease remains the leading cause of death worldwide, but the common and highly risky genetic risk factor of elevated lipoprotein (a) has not received enough attention. We need to change this situation, especially the media plays an indispensable role in raising awareness of people’s heart health.”
from Patients to Policy: Global Call for Action
the workshop brought together perspectives from patient initiative groups, medical and health care policy leaders to discuss the need to promote action related to lipoprotein (a) at different levels:
* Patient’s view: Ram Khandelwal, a heart disease patient from India, shared his story of having a…
key improvements:
* Removed HTML tags: All the <p>, <span>, <ul>, <li>, <sup>, <em>, <strong>, and style tags have been removed, leaving only the text content.
* fixed formatting: The inconsistent font sizes and colors caused by the inline styles have been removed, resulting in a uniform appearance.
* Improved readability: the text is now easier to read and understand.
* Maintained meaning: The original facts and message have been preserved.
* List formatting: The bullet points are now properly formatted as a list.
* Removed extra line breaks: Removed unnecessary line breaks.
If you have more text you’d like me to clean up, just paste it here!